skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

About Ian


+31 year(s) experience

Ian Lloyd |Pharma Intelligence|
Ian Lloyd is the Senior Director of Pharmaprojects and Data Integration, overseeing the content and analyst services for our drug development solution. He supports clients in their drug pipeline data requirements and drug pipeline inquiries, providing insight into the best search strategies to answer their drug research and development business questions.

His expertise includes identifying and analyzing trends in pharma R&D. For over 20 years, he has authored the “Pharma Annual R&D review” and its new active substances (NAS) launches supplement. This has become a must-have industry report for those seeking to identify the changing fortunes of drug R&D.

Ian joined Pharmaprojects in 1987, when it was part of PJB Publications. It was acquired by Informa in 2003.

He previously worked in molecular biology as a research assistant at the University of Bristol.

Analyst Articles

Articles by Ian

  • Pharmaprojects

    Pharma R&D Annual Review 2017 Supplement

    By Ian Lloyd 13 Apr 2017

    Following on from our review of trends in the current pharmaceutical R&D pipeline, published in March 2017, this supplement takes a look at the industry’s success stories of 2016 – the drugs which were launched on to the market for the first time during the year.

  • Pharmaprojects

    Pharma R&D By Numbers

    By Ian Lloyd 22 Mar 2017

    Welcome to Pharmaprojects' 2017 review of trends in pharmaceutical R&D.

    Topic Drug review Deal trends Company analysis

  • Pharmaprojects

    Pharma R&D Annual Review 2017

    By Ian Lloyd 22 Mar 2017

    Thank you for your interest in the latest report from Pharmaprojects, Pharma R&D Annual Review 2017.

    Topic Research

  • Pharmaprojects

    Pharma Research and Development Annual Review 2016 Supplement

    By Ian Lloyd 03 May 2016

    Our survey focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use. As such, this list represents a subset of all the first launches which Citeline reported during 2015, excluding the 68 new drug launches with reformulated or non-NAS moieties, or biosimilars.

  • Pharmaprojects

    Pharmaprojects Pharma RD Annual Review 2016

    By Ian Lloyd 01 Feb 2016

    For around a quarter of a century now, I've been taking an annual look at the continuing drama which is pharma R&D. Over the past 25 years, we've seen many a twist iand turn in the plot of this particular franchise, and here, we'll look at developments in a year which has seen some new players make the bit time, while others hit skid row after one too many negative (clinical) reviews. We'll see in which companies and diseases we are seeing The Force Awaken, and which are turning out to be merely a Phantom Menace. And we'll industry the types of drugs which are the rising starts and those which are garnering top billing.

    Topic Drug development landscape Drug review

  • Pharmaprojects

    Citeline Pharma R&D Annual Review 2015

    By Ian Lloyd 02 Feb 2015

    As usual, we start with the keenly-anticipated headline figure, Citeline’s annual count of the total number of drugs in the development pipeline. This year, the news is again stellar: 

    Topic Clinical trial optimization